Enolicam sodium
Enolicam sodium is a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), with a COX IC50 of 1.5 μM and a 5-LOX IC50 of 3.5 μM. Enolicam sodium inhibits arachidonic acid metabolism via the COX and 5-LOX pathways. Enolicam sodium inhibits the production of reactive oxygen species (ROS), superoxide anions, hydrogen peroxide, and the release of polymorphonuclear leukocytes. Enolicam sodium is applicable to research related to acute oxidative lung injury and ocular inflammation.
For research use only. We do not sell to patients.
- CAS No.: 59756-39-7
- Formula: C17H11Cl3NNaO4S
- Molecular Weight:454.69
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
COX 1.5 μM (IC50) |
5-LOX 3.5 μM (IC50) |
In Vitro
Enolicam (0.1 mM; 16-70 min) sodium moderately inhibits reactive oxygen species generation by 24-hour mouse peritoneal exudate cells in both Lucigenin (HY-D0720)- and Luminol (HY-15922)-amplified chemiluminescence assays[1].
Enolicam sodium potently inhibits cyclooxygenase (IC50 = 1.5 μM) and 5-lipoxygenase (IC50 = 3.5 μM) in a cell-free biochemical assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 59756-39-7
-
Molecular Weight 454.69
-
Formula C17H11Cl3NNaO4S
-
SMILES
O=C(C1=C(C2=C(S(=O)(CC1)=O)C=CC(Cl)=C2)O[Na])NC3=CC=C(C(Cl)=C3)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)